Close

Acorda Therapeutics (ACOR) Tops Q4 EPS by 9c, Provides 2013 Outlook

February 13, 2013 6:58 AM EST Send to a Friend
Acorda Therapeutics (NASDAQ: ACOR) reported Q4 EPS of $0.24, $0.09 better than the analyst estimate of $0.15. Revenue for the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login